Member Info for HOMER1234

Will this share ever move up. Its been an awful investment. Sick of hearing about presentations and waffle about share holder value.

Well were going anywhere until we get a commercial deal or a big pharma buying in.

Few people moving on as I cant see the new investors selling at a loss.

So pleased we bought the other company last year that we never hear of again. I have even forgotten the name.

Well all the new major shareholders control the company these days. Volume is pitiful at the moment. Company IMHO will drift and then be bought out on the cheap. Nigel is clueless and certainly is not pulling the strings these days.

Atleast they have given a proper time frame. Another big day of buying. £7.50. CEO should stop saying share holder value as its insulting.

Six trades just over £10. lol Wake me up next year.

Yes but the only way they will make money most of these directors is getting the product to market. Releasing stock options.

This is all being lined up for something by all the big investors. Just hope were all alive when it happens.

The updates from the company have been pitiful. Results very late this year. Shouldn't take long on the income side of the ledger.

Well these people certainly have the experience to deliver. Extremely positive.

Any direct director's dealings would have to be declared.

Were on Cunard a couple of times this year. Agree about pricing.

P/O is definitely losing the plot these days. Its nothing like the old days and needs a revamp of the entire product.

Yes things change but last time it was really poor. Never again would rather stay at home.

I was expecting some sort of update on the new part of the business.

Unless I missed it the last update was July 2024. That's a long three months.

Nanogenics has now submitted an application to the U.S. Food and Drug Administration ("FDA") to obtain orphan drug designation for its product ECP105, for the prevention of scarring following glaucoma surgery. Obtaining orphan drug status in the USA is expected to bring substantial cost and time savings on the development work and once approved, seven years of exclusivity. A decision is expected by the FDA three months from the date of application.

Yes but the mice will be tax deductible. So its not all bad.

Sorry but that's your only post about EME in a month. Rather wait for official news not bs.

Very good news. Well all the people who bought in the placement and those big trades last week were given prior notice of this RNS.

The annual results will now come out in a timely fashion. AIM and its finest.

Totally agree. They must have an update soon.

Apparently they have 6 months from the end of the fiscal year to publish the annual results to shareholders.

Yes but every year they have been posted later. Should be posted by the end of April. But this is AIM.

Leicester did say "hope".

Get the price as low as possible with no updates and low placings.

Then let all the mates in who hoover up the low placement with ridiculous warrants attached at rubbish prices to get a load more shares at cheap levels.

Sums up AIM . CEO and the new director make a perfect match.

All you can do is buy some more and hope it goes up. Not for me sick of all of bolloksss

So the new investment comes from Tracarta Limited which also bought a big holding in TheraCryf.

Alistair Smith is the new Non Executive Chairman on TheraCrfy.

Wonder if he is also involved in Tracarta Ltd .

Excellent news. Filter button works fine.

Well the company is fully funded for sometime. Still have no idea who has bought all these shares. We have had zero news apart from the placement since last year. Very poor.